Abiomed provides multi-year grant to Boston Children's Hospital Heart Center

Published on:

Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported its donation of an unrestricted grant in the amount of $375,000 to Boston Children's Hospital Heart Center, a newly dedicated cardiovascular care center founded within Boston Children's Hospital. 

The Boston Children's Hospital Heart Center integrates all pediatric specialists related to a patient's care in order to treat both the heart and the whole child. This organizational structure allows for a more focused clinical approach and a fully aligned research effort so that new therapies have the best chance of treating today's patients. Abiomed's funding will help support research and education initiatives of the Heart Center's Advanced Cardiac Therapies (ACT) Program. Among the uses of these funds, the following scientific and clinical goals will be pursued: 

  --  Advance the understanding of basic pathophysiology and symptom correlation in pediatric acute decompensated heart failure patients.

  --  Engage key opinion leaders to assess the potential for multi-center registries and improved methodologies for monitoring neurologic function and quality of life for pediatric patients who receive mechanical circulatory support.

  --  Investigate new cellular and genomic cardiac regeneration therapies that will stimulate myocardial recovery. 

"We are very thankful for Abiomed's generosity in providing this gift to Boston Children's Hospital Heart Center," said Sandra Fenwick, President and Chief Executive Officer, Boston Children's Hospital. "Boston Children's is a leader and innovator in pediatric cardiology and heart surgery. This grant from Abiomed, supporting our scientific and clinical goals, will help us advance the care of children with advanced heart failure. 

Boston Children's Hospital Heart Center is one of the nation's most active pediatric heart failure and transplant centers, managing some of the most complex pediatric and adult congenital heart failure cases in the world and is consistently ranked number one in Pediatric Cardiology and Heart Surgery by US News & World Report. 

"We are very excited about this area of research for pediatric heart failure patients. Abiomed is pleased to support Boston Children's research and advancements for new, cutting edge technologies in the field of pediatric cardiac care," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. 

* The Impella pediatric device is not approved by the FDA.

Related Content

Medtronic using AI to identify more TAVR patients in need
Tirzepatide linked to significant weight loss, ‘impressive’ diabetes prevention after 3 years
Most heart failure patients miss out on guideline-recommended palliative care
CMS updates outpatient reimbursement policy for Barostim device
American Heart Association announces late-breaking research for Scientific Sessions 2024
Impella ECP confirmed to be safe for high-risk PCI—is FDA approval next?

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."